CCR 20th anniversary commentary: Radioactive drones for B-cell lymphoma

Clinical Cancer Research

Volumn 21, Issue 3, 2015, Pages 493-494

  Knox, Susan J ^a   Levy, Ronald ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IBRITUMOMAB TIUXETAN; RITUXIMAB;

ANIMAL; B CELL LYMPHOMA; CANCER STAGING; CLINICAL TRIAL (TOPIC); DOSIMETRY; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; FOLLICULAR LYMPHOMA; FOOD AND DRUG ADMINISTRATION; HUMAN; ISOTOPE LABELING; LARGE CELL LYMPHOMA; LYMPHOMA, B-CELL; NOTE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RADIATION DOSE DISTRIBUTION; RADIOIMMUNOTHERAPY; RADIOTHERAPY; SALVAGE THERAPY; TIME TO TREATMENT; TREATMENT RESPONSE;

ANIMALS; HUMANS; LYMPHOMA, B-CELL; RADIOIMMUNOTHERAPY; RADIOTHERAPY;

EID: 84964305216     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-2547     Document Type: Note

References (8)

1. Knox SJ, Goris ML, Trisler K, Negrin R, Davis T, Liles TM, et al. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res 1996;2:457-70.
2. Schiele J, Knox SJ, Ruehl W, Goris ML. The effect of unlabeled monoclonal antibody (mAb) on the biodistribution of 131I-anti-idiotype mAb in murine B cell lymphoma. Radiother Oncol 1992;24:169-76.
3. Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, et al. Randomized controlled trial ofyttrium-90-labeled ibritumomab tiuxetan radio immunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002;20:2453-63.
4. Witzig TE, Flinn IW, Gordon LI, Emmanouilides C, Czuczman MS, Saleh MN. Treatment with ibritumomab tiuxetan radio immunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 2002;20:3262-9.
5. Morschhauser F, Radford J, Van Hoof A, Botto B, Rohatiner AZ, Salles G. 90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after amedian follow-up of 7.3 years from the International, Randomized, Phase III First-Linelndolent trial. J Clin Oncol 2013;31:1977-83.
6. Witzig TE, Hong F, Micallef IN, Gascoyne RD, Dogan A, Wagner H Jr, et al. A phase II trial of R-CHOP followed by zevalin radioimmunotherapy for patients with previously untreated stages I and II CD20+ diffuse large cell non-Hodgkin's lymphoma: an Eastern Cooperative Oncology Group study (E3202) [abstract]. In: Proceedings of the 54th ASH Annual Meeting and Exposition; 2012 Dec 8-11; Atlanta, GA. Washington (DC): American Society of Hematology; 2012. Abstract nr 2687.
7. Forstpointner R, Dreyling M. Rituximab maintenance versus radioimmunotherapy consolidation in follicular lymphoma: which, when, and for whom? Curr Hematol Malig Rep 2011;6:207-15.
8. Forero A, Weiden PL, Vose JM, Knox SJ, Lo Buglio AF, Hankins J, et al. Phase I trial of a novel antl-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma. Blood 2004;104:227-36.